{
  "CitationSubset": [
    "IM"
  ],
  "KeywordList": [
    [
      "Kawasaki disease",
      "coronary artery lesion",
      "intravenous immunoglobulin",
      "recurrent fever",
      "smoldering symptoms"
    ]
  ],
  "GeneralNote": [],
  "OtherAbstract": [],
  "SpaceFlightMission": [],
  "OtherID": [],
  "InvestigatorList": [],
  "PMID": "28952328",
  "DateCompleted": {
    "Year": "2019",
    "Month": "07",
    "Day": "01"
  },
  "DateRevised": {
    "Year": "2019",
    "Month": "07",
    "Day": "01"
  },
  "Article": {
    "ArticleDate": [
      {
        "Year": "2017",
        "Month": "02",
        "Day": "01"
      }
    ],
    "Language": [
      "eng"
    ],
    "ELocationID": [
      "10.1177/0009922817694459"
    ],
    "Journal": {
      "ISSN": "1938-2707",
      "JournalIssue": {
        "Volume": "57",
        "Issue": "2",
        "PubDate": {
          "Year": "2018",
          "Month": "Feb"
        }
      },
      "Title": "Clinical pediatrics",
      "ISOAbbreviation": "Clin Pediatr (Phila)"
    },
    "ArticleTitle": "Recurrence of Fever After Initial Intravenous Immunoglobulin Treatment in Children With Kawasaki Disease.",
    "Pagination": {
      "StartPage": "189",
      "EndPage": "192",
      "MedlinePgn": "189-192"
    },
    "Abstract": {
      "AbstractText": [
        "The standard treatment for Kawasaki disease (KD) is high-dose intravenous immunoglobulin (IVIG). Some patients experienced recurrent fever after IVIG following defervescence. However, little is known about the frequency of such episodes and the clinical outcome for such patients. We classified 195 KD patients into 4 groups based on their fever patterns after initial IVIG treatment: group NR (no response), group EF (early recurrent fever within 72 hours after defervescence), group LF (late recurrent fever >72 hours after defervescence), and group GR (good response). We compared the clinical characteristics and laboratory data among these groups retrospectively. Nearly a third of patients had recurrent fever (group EF, n = 45; group LF, n = 11). In two-thirds of these patients, the fever had subsided spontaneously without retreatment; 2 patients in Group LF with smoldering KD symptoms had developed coronary artery lesions (CALs) even after additional IVIG. Recurrent fever and smoldering symptoms might be risk factors for CAL."
      ]
    },
    "AuthorList": [
      {
        "Identifier": [],
        "AffiliationInfo": [
          {
            "Identifier": [],
            "Affiliation": "1 National Center for Child Health and Development (NCCHD) Tokyo, Japan."
          }
        ],
        "LastName": "Yoshida",
        "ForeName": "Masanori",
        "Initials": "M"
      },
      {
        "Identifier": [],
        "AffiliationInfo": [
          {
            "Identifier": [],
            "Affiliation": "1 National Center for Child Health and Development (NCCHD) Tokyo, Japan."
          }
        ],
        "LastName": "Oana",
        "ForeName": "Shinji",
        "Initials": "S"
      },
      {
        "Identifier": [],
        "AffiliationInfo": [
          {
            "Identifier": [],
            "Affiliation": "1 National Center for Child Health and Development (NCCHD) Tokyo, Japan."
          }
        ],
        "LastName": "Masuda",
        "ForeName": "Hiroshi",
        "Initials": "H"
      },
      {
        "Identifier": [],
        "AffiliationInfo": [
          {
            "Identifier": [],
            "Affiliation": "1 National Center for Child Health and Development (NCCHD) Tokyo, Japan."
          }
        ],
        "LastName": "Ishiguro",
        "ForeName": "Akira",
        "Initials": "A"
      },
      {
        "Identifier": [],
        "AffiliationInfo": [
          {
            "Identifier": [],
            "Affiliation": "1 National Center for Child Health and Development (NCCHD) Tokyo, Japan."
          }
        ],
        "LastName": "Kato",
        "ForeName": "Hitoshi",
        "Initials": "H"
      },
      {
        "Identifier": [],
        "AffiliationInfo": [
          {
            "Identifier": [],
            "Affiliation": "1 National Center for Child Health and Development (NCCHD) Tokyo, Japan."
          }
        ],
        "LastName": "Ito",
        "ForeName": "Shuichi",
        "Initials": "S"
      },
      {
        "Identifier": [],
        "AffiliationInfo": [
          {
            "Identifier": [],
            "Affiliation": "1 National Center for Child Health and Development (NCCHD) Tokyo, Japan."
          }
        ],
        "LastName": "Kobayashi",
        "ForeName": "Tohru",
        "Initials": "T"
      },
      {
        "Identifier": [],
        "AffiliationInfo": [
          {
            "Identifier": [],
            "Affiliation": "2 National Research Institute for Child Health and Development, Tokyo, Japan."
          }
        ],
        "LastName": "Abe",
        "ForeName": "Jun",
        "Initials": "J"
      }
    ],
    "PublicationTypeList": [
      "Journal Article",
      "Research Support, Non-U.S. Gov't"
    ]
  },
  "MedlineJournalInfo": {
    "Country": "United States",
    "MedlineTA": "Clin Pediatr (Phila)",
    "NlmUniqueID": "0372606",
    "ISSNLinking": "0009-9228"
  },
  "ChemicalList": [
    {
      "RegistryNumber": "0",
      "NameOfSubstance": "Immunoglobulins, Intravenous"
    }
  ],
  "MeshHeadingList": [
    {
      "QualifierName": [],
      "DescriptorName": "Age Distribution"
    },
    {
      "QualifierName": [],
      "DescriptorName": "Child"
    },
    {
      "QualifierName": [],
      "DescriptorName": "Child, Preschool"
    },
    {
      "QualifierName": [],
      "DescriptorName": "Cohort Studies"
    },
    {
      "QualifierName": [],
      "DescriptorName": "Dose-Response Relationship, Drug"
    },
    {
      "QualifierName": [],
      "DescriptorName": "Female"
    },
    {
      "QualifierName": [
        "drug therapy",
        "epidemiology",
        "physiopathology"
      ],
      "DescriptorName": "Fever"
    },
    {
      "QualifierName": [],
      "DescriptorName": "Humans"
    },
    {
      "QualifierName": [
        "therapeutic use"
      ],
      "DescriptorName": "Immunoglobulins, Intravenous"
    },
    {
      "QualifierName": [],
      "DescriptorName": "Incidence"
    },
    {
      "QualifierName": [],
      "DescriptorName": "Japan"
    },
    {
      "QualifierName": [],
      "DescriptorName": "Male"
    },
    {
      "QualifierName": [
        "diagnosis",
        "drug therapy"
      ],
      "DescriptorName": "Mucocutaneous Lymph Node Syndrome"
    },
    {
      "QualifierName": [],
      "DescriptorName": "Prognosis"
    },
    {
      "QualifierName": [],
      "DescriptorName": "Recurrence"
    },
    {
      "QualifierName": [],
      "DescriptorName": "Retrospective Studies"
    },
    {
      "QualifierName": [],
      "DescriptorName": "Risk Assessment"
    },
    {
      "QualifierName": [],
      "DescriptorName": "Severity of Illness Index"
    },
    {
      "QualifierName": [],
      "DescriptorName": "Sex Distribution"
    }
  ]
}